文献速递皮肤肿瘤

免疫检查点抑制剂治疗皮肤恶性肿瘤

Immune checkpoint inhibitors to treat cutaneous malignancies.
PubMed 文献 · J Am Acad Dermatol · 2020-05-24

本文综述免疫检查点抑制剂(抗CTLA-4、PD-1、PD-L1)治疗转移性黑色素瘤、皮肤鳞状细胞癌和默克尔细胞癌的适应证、疗效、安全性及证据。讨论了支持伊匹木单抗、帕博利珠单抗、纳武利尤单抗、西米普利单抗和阿维鲁单抗获批的关键研究及进行中的临床试验。

要点

  • 皮肤科医生及患者将更多遇到免疫检查点抑制剂。
  • 可靠预测生物标志物和难治性疾病处理策略仍待解决。
  • 综述涵盖五种药物在皮肤恶性肿瘤中的关键研究。

核心结论

  • 免疫检查点抑制剂在部分皮肤恶性肿瘤患者中产生抗肿瘤反应。

研究设计与样本

  • 继续医学教育系列首篇文章,综述关键研究及临床试验。

主要发现

  • 伊匹木单抗、帕博利珠单抗、纳武利尤单抗、西米普利单抗和阿维鲁单抗获监管机构批准用于不同皮肤恶性肿瘤。

临床怎么用

  • 皮肤科医生需熟悉免疫检查点抑制剂的适应证、疗效和安全性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

As the incidence of cutaneous malignancies continues to rise and their treatment with immunotherapy expands, dermatologists and their patients are more likely to encounter immune checkpoint inhibitors. While the blockade of immune checkpoint target proteins (cytotoxic T-lymphocyte-associated protein-4, programmed cell death-1, and programmed cell death ligand-1) generates an antitumor response in a substantial fraction of patients, there is a critical need for reliable predictive biomarkers and approaches to address refractory disease. The first article of this Continuing Medical Education series reviews the indications, efficacy, safety profile, and evidence supporting checkpoint inhibition as therapeutics for metastatic melanoma, cutaneous squamous cell carcinoma, and Merkel cell carcinoma. Pivotal studies resulting in the approval of ipilimumab, pembrolizumab, nivolumab, cemiplimab, and avelumab by regulatory agencies for various cutaneous malignancies, as well as ongoing clinical research trials, are discussed.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Barrios DM, Do MH, Phillips GS, et al. Immune checkpoint inhibitors to treat cutaneous malignancies. J Am Acad Dermatol. 2020. PMID: 32461079. doi:10.1016/j.jaad.2020.03.131

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。